# A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of VX-661 in Combination With Ivacaftor

> **NCT02347657** · PHASE3 · COMPLETED · sponsor: **Vertex Pharmaceuticals Incorporated** · enrollment: 510 (actual)

## Conditions studied

- Cystic Fibrosis

## Interventions

- **DRUG:** VX-661 Plus Ivacaftor Combination
- **DRUG:** Ivacaftor
- **DRUG:** VX-661 Plus Ivacaftor Combination Placebo
- **DRUG:** Ivacaftor placebo

## Key facts

- **NCT ID:** NCT02347657
- **Lead sponsor:** Vertex Pharmaceuticals Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-01
- **Primary completion:** 2017-01-20
- **Final completion:** 2017-01-20
- **Target enrollment:** 510 (ACTUAL)
- **Last updated:** 2018-06-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02347657

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02347657, "A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of VX-661 in Combination With Ivacaftor". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT02347657. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*